Clinical Question: Does intravenous iron given to anaemic patients (haemoglobin [Hb] <130 g/L for men and 120 g/L for women) before major elective open abdominal surgery reduce the need for blood transfusions or death within 30 days of surgery?
Evidence From Trial: There were no significant differences in the rates of blood transfusion or death at 30 days after the index operation between anaemic patients who received intravenous iron preoperatively and those who did not.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/tme.12802 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity.
Am J Hematol
January 2025
Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Preoperative intravenous versus oral iron supplementation for elective surgery: evidence based on 12 randomized trials.
Postgrad Med
January 2025
Orthopaedic Department, Peking University First Hospital, Beijing, China.
Aim: This study aims to clarify hematological parameters, transfusion requirements, and adverse events of preoperative intravenous (IVIS) versus oral iron supplementation (OIS) in elective surgery patients.
Methods: We conducted a comprehensive literature search across multiple databases up to 10 December 2023. Twelve RCTs involving 930 participants met our eligibility criteria.
Association between iron deficiency and fertility.
Acta Obstet Gynecol Scand
January 2025
Dextra Fertility Clinic, Helsinki, Finland.
Introduction: This retrospective, observational cohort study investigated the association between treatment of iron deficiency with conception results and pregnancy outcomes in women with infertility and iron deficiency, before and after intravenous ferric carboxymaltose infusion.
Material And Methods: Data were collected from electronic health records from the Dextra Fertility Clinic (Helsinki, Finland) between 2015 and 2020. The cohort included 292 women (<43 years) with infertility and iron deficiency (s-ferritin ≤30 μg/L), treated with a ferric carboxymaltose infusion (Ferinject®, 500 mg i.
Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial.
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Fe3O4-viral-like Mesoporous Silica Nanoparticle(Fe3O4-vMSN)-Sustained Release of Lenvatinib for Targeted Treatment of Hepatocellular Carcinoma.
Curr Cancer Drug Targets
January 2025
Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai, 200135, China.
Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!